Lilly Announces Positive Top-Line Results for Taltz(R) (ixekizumab) vs. Humira(R) (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis

INDIANAPOLIS, Dec. 17, 2018 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today Taltz® (ixekizumab) met the primary and all major secondary endpoints in the Phase 3b/4 SPIRIT-H2H study, which evaluated the ef... Biopharmaceuticals Eli Lilly, Taltz, ixekizumab, psoriatic arthritis, SPIRIT-H2H trial
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news